| Literature DB >> 35715642 |
Carina Riediger1,2,3,4,5, Raphael Hoffmann6, Steffen Löck7, Esther Giehl-Brown6,8,7,9,10, Sandra Dennler6,8,7,9,10, Christoph Kahlert6,8,7,9,10, Jürgen Weitz6,8,7,9,10.
Abstract
BACKGROUND: The number of liver resections is constantly rising over the last decades. Despite the reduction of overall mortality and morbidity in liver surgery, biliary leakage is still a relevant postoperative complication that can lead to a fatal postoperative course. Aim of this analysis is the identification of specific risk factors for postoperative biliary complications after liver resections and the development of a predictive biliary leakage risk score.Entities:
Keywords: Biliary leakage risk score; Hepatectomy; Morbidity; Mortality
Mesh:
Substances:
Year: 2022 PMID: 35715642 PMCID: PMC9568472 DOI: 10.1007/s11605-022-05366-1
Source DB: PubMed Journal: J Gastrointest Surg ISSN: 1091-255X Impact factor: 3.267
Patient’s characteristics and surgical procedures
| Whole cohort | Group 1 | Group 2 | ||||||
|---|---|---|---|---|---|---|---|---|
| % | % | % | ||||||
| Gender | ||||||||
| Male | 553 | 65.5% | 463 | 65.1% | 90 | 67.7% | 0.570 | |
| Female | 291 | 34.5% | 248 | 34.9% | 43 | 32.3% | ||
| Age [years] | 63.5 ± 11.9 | 63.0 ± 12.0 | 66.1 ± 11.1 | 0.006 | ||||
| Body mass index [kg/m2] | 26.8 ± 5.5 | 26.8 ± 5.4 | 26.9 ± 5.7 | 0.778 | ||||
| ASA Classification | ASA I | 13 | 1.5% | 13 | 1.8% | 0 | 0% | 0362 |
| ASA II | 291 | 34.5% | 246 | 34.6% | 45 | 33.8% | ||
| ASA III | 535 | 63.4% | 447 | 62.9% | 88 | 66.2% | ||
| ASA IV | 3 | 0.4% | 3 | 0.4% | 0 | 0% | ||
| Diabetes mellitus | 224 | 26.5% | 185 | 26.0% | 39 | 29.3% | 0.428 | |
| Renal insufficiency | 115 | 13.6% | 95 | 13.4% | 20 | 15.0% | 0.605 | |
| Smoking | 116 | 13.7% | 100 | 14.1% | 16 | 12.0% | 0.532 | |
| Alcohol abuse | 46 | 5.5% | 44 | 6.2% | 2 | 1.5% | 0.029 | |
| Aspirine intake | 101 | 12.0% | 81 | 11.4% | 20 | 15.0% | 0.235 | |
| CASH | 46 | 5.5% | 35 | 4.9% | 11 | 8.3% | 0.118 | |
| Liver fibrosis or cirhosis | 429 | 50.8% | 352 | 49.5% | 77 | 57.9% | 0.076 | |
| Preceeding liver resection | 218 | 25.8% | 187 | 26.3% | 31 | 23.3% | 0.469 | |
| Neoadjuvant chemotherapy | 154 | 18.3% | 135 | 19.0% | 19 | 14.3% | 0.198 | |
| Neoadjuvant antibody treatment | 11 | 1.3% | 10 | 1.4% | 1 | 0.8% | 0.541 | |
| Neoadjuvante combined chemo- and antibody therapy | 187 | 22.2% | 157 | 22.1% | 30 | 22.6% | 0.904 | |
| Monotherapy FOLFOX | 48 | 5.7% | 39 | 5.5% | 9 | 6.8% | 0.558 | |
| Monotherapy FOLFIRI | 12 | 1.4% | 12 | 1.7% | 0 | 0% | 0.131 | |
| Monotherapy 5-FU | 8 | 1.0% | 6 | 0.8% | 2 | 1.5% | 0.471 | |
| Monotherapy FOLFOXIRI | 33 | 3.9% | 32 | 4.5% | 1 | 0.8% | 0.041 | |
| Combined treatment FOLFOX und cetuximab | 25 | 3.0% | 17 | 2.4% | 8 | 6.0% | 0.024 | |
| Combined treatment FOLFIRI und cetuximab | 33 | 3.9% | 28 | 3.9% | 5 | 3.8% | 0.922 | |
Combined treatment FOLFIRI und Bevacizumab | 14 | 1.7% | 12 | 1.7% | 2 | 1.5% | 0.879 | |
| Preoperative interventions | 160 | 19.0% | 124 | 17.4% | 36 | 27.1% | 0.009 | |
PVE TACE ERCP + Stent/ PTCD | 115 | 13.6% | 93 | 13.1% | 22 | 16.5% | 0.003 | |
| 18 | 2.1% | 13 | 1.8% | 5 | 3.8% | |||
| 19 | 2.3% | 11 | 1.6% | 8 | 6.0% | |||
| Diagnosis | ||||||||
| Colorectal liver metastases | 417 | 49.4% | 358 | 50.4% | 59 | 44.4% | 0.205 | |
| Hepatocellular carcinoma | 153 | 18.1% | 135 | 19.0% | 18 | 13.5% | 0.134 | |
| Cholangiocarcinoma (overall) | 175 | 20.7% | 126 | 17.7% | 49 | 36.8% | < 0.001 | |
Gall bladder carcinoma Intrahepatic cholangiocarcinoma Klatskin tumor | 23 | 2.7% | 18 | 2.5% | 5 | 3.8% | 0.425 | |
| 109 | 12.9% | 84 | 11.8% | 25 | 18.8% | 0.028 | ||
| 43 | 5.1% | 24 | 3.4% | 19 | 14.3% | < 0.001 | ||
| Neuroendocrine liver metastases | 32 | 3.8% | 31 | 4.4% | 1 | 0.8% | 0.046 | |
| NCNN liver metastases | 65 | 7.7% | 60 | 8.4% | 5 | 3.8% | 0.063 | |
| Surgical procedures | ||||||||
| Major resection | 347 | 41.1% | 262 | 36.9% | 85 | 63.9% | < 0.001 | |
| ALPPS | 45 | 5.3% | 36 | 5.1% | 9 | 6.8% | 0.422 | |
| Minor resection (overall) | 435 | 51.5% | 397 | 55.8% | 38 | 28.6% | < 0.001 | |
| Minor anatomical resection | 176 | 20.9% | 159 | 22.4% | 17 | 12.8% | 0.013 | |
| Number of segments in anatomical minor resections | 2.05 ± 1.99 | 1.89 ± 1.95 | 2.94 ± 1.98 | < 0.001 | ||||
| Minor non-anatomical resection | 259 | 30.7% | 238 | 33.5% | 21 | 15.8% | < 0.001 | |
| Number of segments in non-anatomical minor resections | 2.21 ± 1.68 | 2.24 ± 1.72 | 1.95 ± 1.07 | 0.238 | ||||
| Operating time (min) | 265.8 ± 133.1 | 252.4 ± 126.0 | 337.5 ± 146.7 | 0.012 | ||||
| Pringle clamping | 189 | 22.4% | 156 | 21.9% | 33 | 24.8% | 0.466 | |
| VCI clamping | 111 | 13.2% | 82 | 11.5% | 29 | 21.8% | 0.001 | |
| VCI resection | 50 | 5.9% | 36 | 5.1% | 14 | 10.5% | 0.014 | |
| Biliodigestive anastomosis | 100 | 11.9% | 62 | 8.7% | 38 | 28.6% | < 0.001 | |
| Portal vein reconstruction | 22 | 2.6% | 11 | 1.6% | 11 | 8.3% | < 0.001 | |
| Hepatic artery reconstruction | 8 | 1.0% | 4 | 0.6% | 4 | 3.0% | 0.008 | |
| Lymph node dissection | 264 | 31.3% | 213 | 30.0% | 51 | 38.4% | 0.055 | |
| Intraoperative transfusion of PRBC | 0.78 ± 1.75 | 0.68 ± 1.63 | 1.32 ± 2.20 | < 0.001 | ||||
| Intraoperative transfusion of platelets | 0.04 ± 0.28 | 0.03 ± 0.23 | 0.10 ± 0.48 | 0.049 | ||||
| Intraoperative transfusion of FFP | 1.30 ± 2.77 | 1.14 ± 2.62 | 2.14 ± 3.36 | < 0.001 | ||||
ASA Amercian Association of Anesthesiologists, CASH chemotherapy-associated steatohepatitis, PVE portal vein embolization, TACE transarterial chemoembolization, ERCP endoscopic retrograde cholangiopancreatociscopy, PTCD percutaneous transhepatic cholangio drain, NCNN non-colorectal, non-neuroendocrine, ALPPS associating liver partition and portal vein ligation for staged hepatectomy, VCI vena cava inferior, PRBC packed red blood cells, FFP fresh frozen plasma
Postoperative data
| Whole cohort | Group 1 | Group 2 | ||||||
|---|---|---|---|---|---|---|---|---|
| % | % | % | ||||||
| Surgical revision | Excluding ISGL Grade C leakage | 99 | 11.7% | 67 | 9.4% | 32 | 24.1% | < 0.001 |
| Including ISGL Grade C leakage | 125 | 14.8% | 67% | 9.4% | 58 | 43.6% | < 0.001 | |
| ICU stay [days] | Median 1 IQR 0.0–4.0 | Median 1 IQR 1.0–3.0 | Median 4 IQR 2.0–12.75 | < 0.001 | ||||
| Hospital stay [days] | Median 13 IQR 9.0–23.0 | Median 12 IQR 9.0–12.0 | Median 26 IQR 16.25–45.0 | < 0.001 | ||||
| 30-day mortality | 36 | 4.3% | 24 | 3.4% | 12 | 9.0% | 0.003 | |
| Postoperative occurrence of septical complications | 44 | 5.2% | 25 | 3.5% | 19 | 14.3% | < 0.001 | |
| Complications according to Clavien | ||||||||
| I | 54 | 6.4% | 45 | 6.3% | 9 | 6.8% | < 0.001 | |
| II | 71 | 8.4% | 56 | 7.9% | 15 | 11.3% | ||
| III | 149 | 17.7% | 81 | 11.4% | 68 | 51.1% | ||
| IV | 40 | 4.7% | 18 | 2.5% | 22 | 16.5% | ||
| V | 50 | 5.9% | 31 | 4.4% | 19 | 14.3% | ||
| Number of complications | ||||||||
| 1 | 145 | 17.2% | 120 | 16.9% | 25 | 18.8% | < 0.001 | |
| 1–3 | 128 | 15.2% | 80 | 11.3% | 48 | 36.1% | ||
| > 3 | 91 | 10.8% | 31 | 4.4% | 60 | 45.1% | ||
ISGL International Study Group of Liver Surgery, ICU intensive care unit
Significant parameters for poostoperative biliary leakage after multivariate logistic regression analysis
| Parameter | Regression coefficient | Odd’s ratio (95% CI) | |
|---|---|---|---|
| Age | 0.026 | 1.026 (1.007–1.047) | 0.008 |
| Major resection | 0.841 | 2.320 (1.489–3.614) | < 0.001 |
| Combined treatment FOLFOX und Cetuximab | 1.253 | 3.500 (1.393–8.794) | 0.008 |
| Operating time | 0.004 | 1.004 (1.003–1.006) | < 0.001 |
| Constant | − 5.039 | 0.006 | < 0.001 |
CI confidence interval
Fig. 1a Receiver operating characteristics (ROC) curve for the probability for occurrence of postoperative bile leakage with a specificity of 67.4% and sensitivity of 70.7% based on the development cohort. b The ROC curve for the validation cohort. The area under the curve is 0.755 (95CI 0.641–0.870). Given the asymptotic CI > 0.5 demonstrates the positive validation of the BLRS. Based on the calculated Youden index of 0.149 with a sensitivity of 68.2% and a specificity of 75.8%
Biliary leakage risk score (BLRS) based on the development cohort (n = 844 patients)
| BLRS model | BLRS | Risk according to BLRS (in %) | POBL | Odd’s ratio (95% CI) | |||
|---|---|---|---|---|---|---|---|
| % | |||||||
| 2-stage (Binary) | < 0.149 | < 15% | 518 | 39 | 7.5% | ||
| ≥ 0.149 | > 15% | 326 | 94 | 28.8% | 4.976 (3.319–7.460) | < 0.001 | |
BLRS biliary leakage risk score, POBL postoperative biliary leakage, CI confidence interval
Validation of the biliary leakage risk score applied to the validation chort (n = 142)
| BLRS model | BLRS | Risk according to BLRS (in %) | POBL | Odd’s ratio (95% CI) | |||
|---|---|---|---|---|---|---|---|
| % | |||||||
| 2-stage (Binary) | < 0.149 | < 15% | 98 | 7 | 7.1% | ||
| ≥ 0.149 | > 15% | 44 | 15 | 34.1% | 6.724 (2.499–18.091) | < 0.001 | |
BLRS biliary leakage risk score, POBL postoperative biliary leakage, CI confidence interval